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Summary Increased severity of illness among hospitalised patients and an ageing popu-
lation have led to an increased incidence of hospital acquired infections and represent a
signiﬁcant challenge to the clinician in terms of managing infections. The collateral damage
which can occur with antibiotic therapy is also an important consideration when initiating
empirical antibiotic therapy, particularly in patients who are seriously ill or immunocom-
promised. Collateral damage is the term used to describe the adverse ecological effects
of antibiotic therapy, such as the selection of drug-resistant organisms, and the adverse
events associated with antibiotic therapy such as Clostridium difﬁcile disease. Antibiotic
use and ineffective infection control have been implicated in the development and spread
of resistant Gram-positive and Gram-negative bacterial pathogens which are associated
with increased mortality and morbidity, prolonged hospitalisation and increased costs.
Carbapenem consumption and mechanical ventilation have been linked to colonisation or
infection with problematic organisms including methicillin-resistant Staphylococcus aureus,
Pseudomonas aeruginosa and Stenotrophomonas maltophilia, while cephalosporin use has
been associated with evolution of infections due to vancomycin-resistant enterococci
(VRE) and Gram-negative bacilli producing extended-spectrum b-lactamases (ESBL), and
to colonisation or superinfection with Clostridium difﬁcile. The safety proﬁle of antibiotics
must also be taken into consideration when selecting therapy, and single broad-spectrum
agents may provide excellent coverage with a low risk of adverse events. The use of
single agents may be associated with lower costs, improved ease of administration and
fewer drug–drug interactions. However, in an environment of increasing resistance, initial
aggressive therapy may be required to avoid excessive mortality and morbidity. Ideally
antibiotic therapy should be directed by culture and knowledge of local susceptibility
patterns. Before culture results are available therapy may need to be initiated empirically
to cover the likely pathogens. In neutropenic patients with fever the current guidelines
recommend the use of empirical therapy at the onset of fever for all patients. Where
no aetiology is identiﬁed, antibiotic therapy should continue for at least 2 weeks while
aggressive attempts are made to deﬁne the source of fever. When the aetiology of infection
has been identiﬁed, therapy should be adjusted to provide optimal treatment with the best
safety proﬁle and lowest cost. The principal of avoiding collateral damage provides a useful
framework for selecting antibiotics for empirical therapy in today’s changing environment.
© 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.
* Tel: +1 919 966 2536; fax: +1 919 966 1451. E-mail: dweber@unch.unc.edu (D.J. Weber).
1201-9712/$30.00 © 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
S18 D.J. Weber
Background
Current challenges in the management of neutropenic
patients and those in the intensive care unit (ICU) include
the changing aetiology of infection (discussed elsewhere
in this supplement), the changing hospital population
and need for more vigilant infection control measures
because of the rise in resistant organisms. Changes in the
patient population in US hospitals include the following:
(1) increased numbers of immunocompromised patients
due to increases in patients with cancer, solid organ
transplants, or infection with human immunodeﬁciency
virus; (2) increases in patients with chronic diseases
such as cystic ﬁbrosis, diabetes mellitus, and autoimmune
diseases such as lupus erythematosis, rheumatoid arthritis,
and inﬂammatory bowel disease many of whom are also
immunocompromised as a result of their underlying disease
or therapy (e.g., corticosteroids): (3) more patients with
multiple co-morbidities due to an aging population many
of whom reside in care facilities and are therefore more
likely to be colonized with antibiotic resistant pathogens;
and (4) more severely ill patients because of the tendency
to treat patients as out-patients.
In parallel with the increasing severity of illness in
hospitalised patients, the number of hospital-acquired
infections has also increased. The likelihood of developing
a healthcare-associated infection increased between 1975
and 1995 from 7.2 per 1000 hospital days to 9.8 per
1000 hospital days 1. Approximately 1 in 10 hospitalised
patients will acquire an infection after admission, resulting
in substantial economic cost 2. Estimates of the cost of
these infections, at 2002 prices, suggest that the annual
economic burden is $6.7 billion per year in the USA and
£1.06 billion (approximately $1.7 billion) in the United
Kingdom 2, representing 0.06% and 0.10% of gross domestic
product (GDP), respectively. Although in many instances
length of hospitalisation has decreased, there has been an
increase in the size and number of ICUs and in specialised
facilities for transplants. Major challenges for the future
include antimicrobial use and control of emerging resistant
organisms, more intensive chemotherapy resulting in
more severely immunocompromised patients, ineffective
infection control (especially lack of compliance to
hand hygiene recommendations), and development of
evidence-based recommendations for infection control and
prevention of nosocomial infections 3. Other challenges
include the need for sterilisation protocols to reduce the
possibility of person-to-person transmission of prion agents
following surgery, the possibility of an inﬂuenza pandemic
in the near future (possibly due to an H5N1 strain), the
potential for the intentional use of bioterrorism agents,
and, in the future, the potential for zenotransplantation
(i.e., use of animal organs in humans).
In the USA two million healthcare-associated infections
are reported annually, with a cumulative incidence of
~10%, and are the sixth leading cause of death in the United
States 4. Over a 22-year period the frequency of sepsis
has increased from 82.7 cases per 100,000 population in
1979 to 240.4 cases per 100,000 in 2000 5. Data from the
National Nosocomial Infections Surveillance (NNIS) system
managed by the Centers for Disease Control and Prevention
(CDC) reported a 11% increase in 2003 relative to 1998–2002
in Staphylococcus aureus that are resistant to methicillin
(i.e., MRSA) to approximately 60%, and a 47% increase in
Klebsiella pneumoniae isolates resistant to 3rd-generation
cephalosporins to over 20% 4. The same reported noted a
12% increase in vancomycin-resistant enterococci (VRE) to
28.5%, a 15% increase in imipenem-resistant Pseudomonas
aeruginosa to 21.1%, and a 20% increase in 3rd-generation
cephalosporin resistant P. aeruginosa to 31.9%. In Europe
the frequency of infections occurring in ICU patients has
risen from 44.8% in 1995 6 to 64.0% in 2002 7. The most
common site of infection was the lung (68%) followed
by the abdomen (22%), bloodstream (20%) and urinary
tract (14%). In patients with sepsis, Gram-positive cocci
were isolated from 40% of patients, Gram-negative bacilli
from 38% and fungi from 17%. In contrast to neutropenic
patients, exogenous ﬂora are a major source of infection
in the ICU, often being passed by healthcare workers and
patients as a result of poor hand hygiene or inadequate
infection control policies 8. In addition ~15% of blood
cultures yield Candida species, the most common infecting
pathogen being Candida albicans 9.
Appropriate antibiotic selection
The importance of appropriate empirical antibiotic therapy
has been clearly documented in the literature 10-15.
Empirical therapy also needs to consider the likelihood
of the patient being infected with a resistant pathogen.
As previously noted, NNIS has reported a 47% in-
crease in extended-spectrum b-lactamase (ESBL) producing
K. pneumoniae from 2003 compared with 1998–2002 with
20.6% of isolates being resistant to a 3rd-generation
cephalosporin or aztreonam 4. Over the same time
period, resistance to cephalosporins, ﬂuoroquinolones and
carbapenems increased by 20%, 9% and 15%, respectively;
and vancomycin-resistant enterococci increased by 12%
with 28.5% of isolates being reported as resistant. The
same data reported 59.5% of S. aureus as methicillin-
resistant and 89.1% of coagulase-negative staphylococci
as methicillin-resistant. Other data show that methicillin-
resistant S. aureus (MRSA) has trebled in less than 20 years,
rising from ~20% in 1987 to 63% in 2003 16. “Collateral
damage” is a term used to refer to the adverse ecological
effects of antibiotic therapy; namely, the selection of
drug-resistant organisms and the unwanted colonisation or
infection with multidrug-resistant organisms 17.
A number of factors contribute to the spread of
resistant isolates. Selection pressures for the development
of resistance include antimicrobial prophylaxis, frequent
empirical antibiotic use, polymicrobial therapy and
prolonged exposure to antibiotic regimens. Hospitalised
patients often have multiple co-morbidities, further
increasing the risk of acquiring resistant pathogens or have
intravenous lines in situ, or other indwelling catheters
(e.g., endotracheal tubes, urinary catheters, etc.). The
high use of broad-spectrum antibiotics in the ICU has
also been associated with the emergence of virulent
organisms, such as Pseudomonas aeruginosa, Acineto-
bacter baumannii, and Stenotrophomonas maltophilia.
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Table 1
Effect of mechanical ventilation and prior antibiotic use on the development of resistant pathogens
Organisms Number (percentage) responsible for 135 VAP episodes classiﬁed according
to duration of mechanical ventilation (MV) and prior antibiotic therapy (ABT)
Group 1 (n = 22)
MV < 7, ABT = no
Group 2 (n = 12)
MV < 7, ABT = yes
Group 3 (n = 17)
MV 7, ABT = no
Group 4 (n = 84)
MV 7, ABT = yes
Multiresistant bacteria 0* 6 (30) 4 (12.5)† 89 (58.6)
P. aeruginosa 0 4 (20) 2 (6.3) 33 (21.7)
A. baumannii 0 1 (5) 1 (3.1) 20 (13.2)
S. maltophilia 0 0 0 6 (3.9)
MRSA 0 1 (5) 1 (3.1) 30 (19.7)
Other bacteria 41 (100) 14 (70) 28 (87.5) 63 (41.4)
*P < 0.02 versus Group 2, 3 or 4; †P < 0.0001 versus Group 4. Adapted from Trouillet 1998 22.
De-escalation, which consists of initial treatment with
broad-spectrum antibiotics to cover the most probable
causative pathogens, followed by antibiotic streamlining
driven by microbiological ﬁndings (isolation by culture with
susceptibility testing of pathogens) is thought to provide
maximum beneﬁt for the individual patient, while reducing
the selection pressure for resistance 18,19. The correlation
between antibiotic use and resistance is well documented
in the literature, and reducing antibiotic use may result in a
decline in the levels of resistance. Lepper et al. 20 reported
a correlation between the consumption of imipenem
and resistance in isolates of P. aeruginosa. Interestingly
these investigators did not ﬁnd a correlation between
levels of resistance and consumption of either ceftazidime
or piperacillin-tazobactam. Carbapenem consumption 21
and mechanical ventilation 22,23 have also been linked to
colonisation or infection with Acinetobacter spp., MRSA,
P. aeruginosa and S. maltophilia (Table 1).
Antibiotic use has also been implicated in the spread
of VRE. In an extensive review of the literature
VRE colonisation and infection were found to occur
predominantly in patients with severe underlying disease,
extended length of hospital stay, and previous antibiotic
exposure 24. This meta-analysis reported that the most
consistently recognised antibiotic agents inducing or
facilitating the acquisition of VRE colonisation or infection
were vancomycin, cephalosporins, and anti-anaerobic
agents. The total number of antibiotic agents and the
duration of antibiotic treatment or prophylaxis were also
identiﬁed as important risk factors for the acquisition of
VRE. In an animal model comparing the effects of different
antibiotics on persistence and density of VRE intestinal
colonization 25, vancomycin, clindamycin, piperacillin-
tazobactam, ticarcillin-clavulanic acid, metronidazole,
cefotetan, ampicillin, and ampicillin-sulbactam promoted
persistent high-density VRE colonisation. Cefepime, ceftri-
axone, aztreonam, and ciproﬂoxacin promoted VRE to a
lesser degree or not at all. These investigators concluded
that antimicrobial activity against anaerobes was the most
important factor for promoting persistent high-density VRE
stool colonisation.
Resistant pathogens are associated with escalating costs
due to prolonged hospitalisation, the need for increased
infection control procedures, including isolation (which
may negatively impact on the psychological well being
of the patient), and in most studies, increased mortality.
Two recent meta-analyses 26,27 and data from the Centers
for Disease Control (CDC) 28 report a signiﬁcant increase
in the mortality associated with methicillin-resistant
S. aureus or VRE infections (p < 0.001). In the presence of
ESBL-producing E. coli and K. pneumoniae, intermediate
susceptibility (MIC 8mg/mL) has been associated with
100% failure of cephalosporins 29.
Adverse events associated with antibiotic
therapy
In critically ill or at risk patients, such as those with
neutropenia, the safety proﬁle of an antibiotic is an
important therapeutic consideration. Adverse reactions
occurring with antibiotic use (Table 2) are usually the
result of (1) dose or duration related toxicity (e.g., renal
toxicity due to an aminoglycoside, thrombocytopenia due
to linezolid) , (2) an immunologic reaction to the drug
or its metabolites (e.g., anaphylaxis to penicillin), or
(3) an idiosyncratic effect of the compound or its metabo-
lites (e.g., tendon rupture due to a ﬂuoroquinolone).
Most antibiotic-related adverse reactions are predictable
and are unwanted toxicities inherent in the antibiotic
compound or its metabolites. Such events are often
dose- or duration-dependent and can be avoided by
appropriate dosage adjustments or limiting the duration of
therapy. Unpredictable reactions may occur independent
of the dose and route of administration and reﬂect such
factors as drug intolerance, allergy, and other idiosyncratic
responses, including aplastic anaemia associated with
chloramphenicol, tendon rupture with the ﬂuoroquinolones
and liver toxicity with trovaﬂoxacin. The choice of an
antibiotic for empirical therapy is based on considerations
of efﬁcacy, safety, and cost. Estimation of efﬁcacy is
based on the nature of the presumed infection (site),
spectrum of the antibiotic(s), epidemiology (age, location
of patient such as ICU), host defences (especially immuno-
compromising disorders), and the local antibiogramme.
Safety concerns include frequency of dose- and duration-
dependent toxicity (this may depend on underlying renal
and/or hepatic impairment) and idiosyncratic reactions.
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Table 2
Adverse events associated with antibiotics
Adverse event Examples
Dose and/or duration related Aminoglycosides (renal dysfunction, dose and duration dependent)
Linezolid (hematologic toxicity, duration >2 weeks)
Penicillins (seizures, doses >40–60 million U/d)
Vancomycin (Red man’s sydrome, rapid infusion)
Gemiﬂoxacin (rash, therapy >7 days)
Ethambutol (optic neuritis, dose >15mg/kg)
5 ﬂucytosine (leukopenia)
Idiosyncratic reactions Chloramphenicol (aplastic anemia)
Fluoroquinolones (tendon rupture)
Sulfonamides (aseptic meningitis)
Isoniazid (liver toxicity)
Allergic reactions Anaphylaxis (all drugs)
Collateral damagea Overgrowth (e.g., C. difﬁcile)
Induction of resistance (e.g., P. aeruginosa)
Selection for resistant pathogen (e.g., MRSA)
a See text for more complete discussion.
Finally, everything else being equal, we should choose the
least expensive antibiotic regimen. Many times a single
broad-spectrum agent will provide excellent coverage with
a low risk of adverse events. The advantages of using a
single broad-spectrum agent include the ability to ascribe
toxicity, ease of administration, reduced likelihood of drug–
drug interactions, and lower cost.
A classical and clinical important example of collateral
damage from antibiotic therapy is the precipitation of
Clostridium difﬁcile associated disease (CDAD). CDAD
is increasing worldwide, and occurs almost entirely
in patients who have received previous antimicrobial
treatment. Pepin et al. 30 reported an increase of 35.6 per
100,000 population in 1991 to 156.3 per 100,000 in 2003.
Among patients aged 65 years or more, it increased
from 102.0 to 866.5 per 100,000. The annual cost of
CDAD in the United States has been estimated at >$1.1
billion (2002 prices) 31. Severe pseudomembranous colitis,
toxic megacolon and fulminant CDAD are life-threatening
complications of C. difﬁcile infection. In an early study of
patients undergoing elective surgical procedures who had
not received prior antibiotic treatment nor reported any
diarrhoeal disease during at least the preceding 3 months,
patients received prophylaxis with a cephalosporin or
mezlocillin or no antibiotic prophylaxis 32. The incidence
of C. difﬁcile and cytotoxin after injection of a single
dose of cephalosporin was 23%. Of patients receiving
cefoperazone, signiﬁcantly more (43.7%, P = 0.04) were
colonised with C. difﬁcile than with other cephalosporins.
Of patients receiving prophylaxis with mezlocillin only
3.3% were colonised, and of patients receiving no
prophylaxis none were colonised.
Antibiotics are not equal in terms of developing
CDAD. CDAD rates signiﬁcantly decrease when clindamycin
or third-generation cephalosporin use is reduced. More
recently, increased CDAD risk has been associated with
ﬂuoroquinolone use. The risk of antibiotic-associated CDAD
increases when C. difﬁcile is antibiotic-resistant, with high-
level ﬂuoroquinolone-resistance as an identiﬁed risk factor.
In 2005, C. difﬁcile hyperproducing toxins A and B was
associated with an outbreak of CDAD 33. Isolates belonging
to one restriction-endonuclease analysis (REA) group (BI)
and having the same pulsed-ﬁeld gel electrophoresis (PFGE)
type (NAP1) were identiﬁed in specimens collected from
patients. BI/NAP1 isolates were of toxinotype III, and
were positive for the binary toxin CDT, and contained
an 18-bp tcdC deletion. Fluoroquinolone-resistance was
more common in BI/NAP1 isolates than in non-BI/NAP1
isolates (100% vs. 42%, P < 0.001), whereas the rate of
resistance to clindamycin was the same in the two
groups (79%). These resistant clones have been associated
with an increased severity of disease 34. A multivariate
analysis of risk factors showed that second-generation
cephalosporins were associated with the highest increase
risk for developing CDAD (OR = 6.0, 95%CI: 2.1–17.5)
(Table 3).
Preventing collateral damage
The CDC’s Campaign to Prevent Antimicrobial Resistance in
Healthcare Settings has identiﬁed 4 strategies to prevent
the spread of resistant pathogens: (1) preventing infection;
(2) preventing transmission; (3) effective diagnosis and
treatment of infection; and (4) optimising the use of
antimicrobials. Key interventions for infection control
include effective hand hygiene using alcohol-based anti-
septics or handwashing products such as those containing
chlorhexidine 3, surveillance systems to monitor and
identify key pathogens and contact precautions including
gloves and gowning for patients with multidrug-resistant
pathogens (e.g., MRSA, VRE, C. difﬁcle), and appropriate
environmental disinfection (especially important with
C. difﬁcile). We also isolate cases colonised or infected
with multidrug resistant Gram negative bacilli if the are
susceptible to less than 2 classes of antimicrobial agents.
Successful interventions to reduce resistance also
include reduction in overall use of antibiotics, espe-
cially third-generation cephalosporins 35. The extensive
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Table 3
Multivariate model of risk factors for developing CDAD 34
lIncreased risk Odds ratio (95%CI) No increased risk Odds ratio (95%CI)
Any cephalosporin 3.8 (2.2–6.6) Clindamycin 1.6 (0.5–4.8)
1st cephalosporin 2.4 (1.2–4.6) Aminoglycosides 0.7 (0.3–1.9)
2nd cephalosporin 6.0 (2.1–17.5) Macrolides 1.3 (0.6–2.9)
3rd cephalosporin 3.0 (1.4–6.8) IV vancomycin 1.3 (0.5–3.1)
Any ﬂuoroquinolone 3.9 (2.3–6.6) Penicillins 0.7 (0.3–2.9)
Ciproﬂoxacin 3.3 1.8–5.4) Carbapenems 1.4 (0.3–6.3)
Gatiﬂoxacin/moxiﬂoxacin 3.4 (1.5–7.7) Penicillin with b-lactamase inhibitor 1.2 (0.7–2.3)
Levoﬂoxacin 0.6 (0.2–1.9)
Table 4
Cephalosporin replacement and reduction in ESBLs
Year Reference Agent Reduction in
cephalosporin use
Replacement agent Intervention successful
(Yes/No)
1993 Meyer 39 Ceftazidime 73% Imipenem-cilastatin Yes
1996 Rice 40 Ceftazidime 50% Piperacillin-tazobactam Yes
1998 Pena 41 3rd-Generation cephalosporin 83% Piperacillin-tazobactam
Imipenem-cilastatin
Yes
1998 Rahal 42 All cephalosporins 80% Imipenem-cilastatin Yes
1999 Landman 43 Ceftazidime
Ceftazidime
89%
66%
Ampicillin-sulbactam
Piperacillin-tazobactam
Yes
2000 Patterson 44 Ceftazidime Hosp. A – 71%
Hosp. B – 27%
Piperacillin-tazobactam Yes
use of third-generation cephalosporin antibiotics has
played an important role in the worldwide emergence
of ESBLs in Gram-negative bacteria 17,36-38. Table 4
summarises publications reporting the effect of replac-
ing cephalosporins with imipenem-cilastatin, ampicillin-
sulbactam or piperacillin-tazobactam on the levels of
resistance. In all these studies, replacing cephalosporins
with alternative agents resulted in a reduction in the
incidence of ESBLs. When these measures are combined
with the active promotion of prescribing guidelines,
appropriate use of antibiotics increases and costs and
duration of hospitalisation decreases 45,46. The use of
a computer program that provides guidelines may also
aid the decision process and has been associated with
signiﬁcant reductions in orders for drugs to which the
patients had reported allergies (35, vs. 146 during the
pre-intervention period; p < 0.01), excess drug dosages
(87 vs. 405, p < 0.01), and antibiotic-susceptibility mis-
matches (12 vs. 206, p < 0.01) 45. Evans and co-workers 45
also noted marked reductions in the mean number of days
of excessive drug dosage (2.7 vs. 5.9, p < 0.002) and in
adverse events caused by anti-infective agents (4 vs. 28,
p < 0.02). They also reported improved outcomes (i.e.,
shorter hospital stay) and reduced cost.
Selecting antibiotics for empirical therapy to which the
likely infecting organisms are susceptible is associated with
a much greater chance of clinical success and improved
patient outcomes than an inappropriate choice. Ideally,
antibiotic therapy should be based on the accurate iden-
tiﬁcation and susceptibility testing of bacteria responsible
for the infection. However, this may take up to 72 hours
due to limitations in current diagnostic methods. The
dilemma for the clinician faced with an infected patient is
that increased multi-resistant organisms mean that broad-
spectrum antibiotics should ideally be used sparingly, yet
prompt aggressive antibiotic treatment is required to
avoid morbidity and mortality. Clinical decisions regarding
empirical antibiotic treatment must be made when the
need to treat is greater than the need to wait for mi-
crobiological conﬁrmation. In clinical practice, this occurs
with most critically ill patients who become febrile. In the
ICU setting, several studies have shown that mortality in
patients who receive inappropriate or inadequate initial
antibiotic therapy is almost double that seen in those
who receive adequate antimicrobial treatment 13,14. In an
ICU-based analysis, inadequate antimicrobial treatment
was the most important independent determinant of
hospital mortality 19. Risk stratiﬁcation studies have shown
that previous antibiotic use, particularly broad-spectrum
antibiotics, and prolonged use of a mechanical ventilator,
signiﬁcantly contribute to increasing patient risk of
developing resistance 22. For this reason, risk needs to be
assessed for each patient before treatment decisions are
made.
Similarly, the Infectious Disease Society of America
(IDSA) 2002 Guidelines for the management of neutropenic
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fever recommend empirical antibiotic therapy for all
neutropenic patients at the onset of fever 47 (see elsewhere
in this supplement). In selecting the initial antibiotic
regimen, the type, frequency of occurrence, and antibiotic
susceptibility of bacterial isolates recovered from other
similar patients in the same hospital should be considered.
The use of certain antibiotics may be limited by special
circumstances, such as drug allergy or organ (e.g.
renal or hepatic) dysfunction. Cisplatin, amphotericin B,
cyclosporine, vancomycin and aminoglycosides should be
avoided in combination because of their additive renal
toxicity. Drug plasma concentrations should be monitored
when they are helpful in predicting therapeutic success
and toxicity (e.g. aminoglycosides). Catheter-associated
bacteraemia due to Bacillus species, P. aeruginosa,
S. maltophilia, Corynebacterium jeikeium, or VRE, and
candidaemia, often respond poorly to antimicrobial
treatment, and prompt removal of the catheter is
recommended, whenever possible. Established infections
with Acinetobacter species also often require removal of
the infected catheter.
Several studies have shown no signiﬁcant differences
between monotherapy and multi-drug combinations for
empirical treatment of uncomplicated episodes of fever
in neutropenic patients 48-54. A third- or fourth-generation
cephalosporin (ceftazidime or cefepime), piperacillin-
tazobactam, or a carbapenem (imipenem-cilastatin or
meropenem) may be used successfully as monotherapy).
However, ESBLs have reduced the utility of ceftazidime
for monotherapy. Cefepime, imipenem-cilastatin, and
meropenem, unlike ceftazidime, have excellent ac-
tivity against viridans streptococci and pneumococci.
Piperacillin-tazobactam has also been found to be effective
as monotherapy 50,54. Patients must be monitored closely
for non-response, emergence of secondary infections,
adverse effects, and the development of drug-resistant
organisms. In particular, the spectrum of drugs usually used
as monotherapy does not usually cover coagulase-negative
staphylococci, MRSA, VRE, some strains of penicillin-
resistant S. pneumoniae, and viridans streptococci.
Summary
Inappropriate antibiotic use and overuse are the main
driving factors for the development of antibiotic resistant
pathogens. Appropriate choice of empiric antibiotics is
associated with decreased mortality, and the choice of
empirical therapy should be guided by the epidemiology
of infection, infecting ﬂora, and local antimicrobial
susceptibility patterns. Appropriate infection control and
antibiotic use can decrease the likelihood of patients
developing antibiotic resistant pathogens. Empirical man-
agement of neutropenic fever has been challenged by the
emergence of resistance. When selecting antibiotics for
managing these patients, three factors should be taken
into consideration: spectrum of activity, the potential to
induce future antibiotic resistance, and adverse events or
toxicity. Antibiotics posseing a tailored spectrum of activity
(i.e., coverage of likely pathogens including antibiotic-
resistant strains) can improve treatment outcomes while
avoiding collateral damage. Also, the use of an antibiotic
with chemical properties that may minimize the risk
of developing resistance should be considered. These
principles provide a useful framework for the empirical
choice of antibiotics. This approach should provide
improved clinical and microbiological outcomes while
decreasing the risk for collateral damage.
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